Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II

Atherosclerosis is regarded as a dynamic and progressive disease arising from the combination of endothelial dysfunction and inflammation.1–6 This article is the second in a 2-part series examining emerging markers of inflammation and endothelial cell activation. The first article7 provided a brief overview of the link between inflammation, endothelial dysfunction, and atherosclerosis and began the examination of emerging inflammatory mediators. This second article continues with an exploration of more novel markers for cardiovascular disease. ### Lectin-Like Oxidized Low-Density Lipoprotein (LDL) Receptor-1 The endothelial injury, activation, and dysfunction caused by oxidized LDL (oxLDL) in the pathogenesis of atherosclerosis are exerted via lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) activation.8,9 LOX-1, initially identified as the major receptor for oxLDL in endothelial cells, can also be expressed in macrophages and smooth muscle cells (SMCs).10–12 It is a type II membrane protein with a C-type lectin–like extracellular domain that can be cleaved, to release the soluble form of LOX-1, by an unknown protease.8 In addition to being the main receptor for oxLDL, LOX-1 has the ability to bind damaged or apoptotic cells, activated platelets, advanced glycation end products, and pathogenic organisms.13–15 Once bound, these ligands can be endocytosed or phagocytosed into the cell. Under physiological conditions, LOX-1 may play a role in host defense or serve to scavenge cellular debris.8 However, in pathological states, LOX-1 may be involved in binding proatherogenic materials, such as oxLDL, that activate the endothelium. With its ability to bind products that induce inflammation and endothelial activation, it is not surprising that elevated LOX-1 expression is observed in both initial and advanced atherosclerotic lesions.16,17 The stage for atherosclerosis is set once endothelial dysfunction occurs. LOX-1 may play a role in initiating and potentiating this crucial first step. Under conditions of hypercholesterolemia, hypertension, and diabetes, disease states that promote vascular injury, …

[1]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[2]  S. Verma,et al.  New Markers of Inflammation and Endothelial Cell Activation: Part I , 2003, Circulation.

[3]  A. Quyyumi,et al.  Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. , 2003, The New England journal of medicine.

[4]  M. Kutryk,et al.  Endothelial progenitor cells: new hope for a broken heart. , 2003, Circulation.

[5]  W. Hofmann,et al.  HMG-CoA Reductase Inhibitors Reduce Senescence and Increase Proliferation of Endothelial Progenitor Cells via Regulation of Cell Cycle Regulatory Genes , 2003, Circulation research.

[6]  A. Morgan,et al.  Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease , 2003, Journal of Molecular Medicine.

[7]  A. Newby,et al.  Statins Inhibit Secretion of Metalloproteinases-1, -2, -3, and -9 From Vascular Smooth Muscle Cells and Macrophages , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[8]  J. Mehta,et al.  LOX-1, an Oxidized LDL Endothelial Receptor, Induces CD40/CD40L Signaling in Human Coronary Artery Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[9]  F. Cambien,et al.  Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease , 2003, Circulation.

[10]  P. Vallance,et al.  Protease-Activated Receptor 2–Mediated Vasodilatation in Humans In Vivo: Role of Nitric Oxide and Prostanoids , 2003, Circulation.

[11]  S. Klarenbach,et al.  Differential Actions of PAR2 and PAR1 in Stimulating Human Endothelial Cell Exocytosis and Permeability: The Role of Rho-GTPases , 2003, Circulation research.

[12]  T. Sawamura,et al.  The platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells. , 2003, Journal of the American College of Cardiology.

[13]  J. Mehta,et al.  LOX-1 Mediates Oxidized Low-Density Lipoprotein-Induced Expression of Matrix Metalloproteinases in Human Coronary Artery Endothelial Cells , 2003, Circulation.

[14]  WolfgangKoenig,et al.  Antidiabetic PPARγ-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease , 2003 .

[15]  A. Takeshita,et al.  Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. , 2003, Cardiovascular research.

[16]  U. Ikeda,et al.  Matrix metalloproteinases and coronary artery diseases , 2003, Clinical cardiology.

[17]  M. D'Andrea,et al.  Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates , 2003, Journal of Pharmacology and Experimental Therapeutics.

[18]  W. Koenig,et al.  Antidiabetic PPAR&ggr;-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease , 2003 .

[19]  Kayo Nakamura,et al.  Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Mehta,et al.  Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells. , 2002, Cardiovascular research.

[21]  S. Coughlin,et al.  PARticipation in inflammation. , 2003, The Journal of clinical investigation.

[22]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[23]  A. Tselepis,et al.  Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. , 2002, Atherosclerosis. Supplements.

[24]  P. Ganz,et al.  Endothelial function. From vascular biology to clinical applications. , 2002, The American journal of cardiology.

[25]  Zaverio M. Ruggeri,et al.  Platelets in atherothrombosis , 2002, Nature Medicine.

[26]  F. Fernández‐Avilés,et al.  Cooperation Between Secretory Phospholipase A2 and TNF-Receptor Superfamily Signaling: Implications for the Inflammatory Response in Atherogenesis , 2002, Circulation research.

[27]  T. Voyno-Yasenetskaya,et al.  Galpha(q) and Gbetagamma regulate PAR-1 signaling of thrombin-induced NF-kappaB activation and ICAM-1 transcription in endothelial cells. , 2002, Circulation research.

[28]  D. Li,et al.  Oxidized Low-Density Lipoprotein Receptor LOX-1 and Apoptosis in Human Atherosclerotic Lesions , 2002, Journal of cardiovascular pharmacology and therapeutics.

[29]  K. Hatakeyama,et al.  Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. , 2002, Thrombosis research.

[30]  M. D'Andrea,et al.  Characterization of Thrombin-Induced Leukocyte Rolling and Adherence: A Potential Proinflammatory Role for Proteinase-Activated Receptor-41 , 2002, The Journal of Immunology.

[31]  T. Sawamura,et al.  LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. , 2002, Pharmacology & therapeutics.

[32]  W. Jaross,et al.  Biological effects of secretory phospholipase A2 group IIA on lipoproteins and in atherogenesis , 2002, European journal of clinical investigation.

[33]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[34]  J. Mehta,et al.  Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. , 2002, Journal of the American College of Cardiology.

[35]  M. Makuuchi,et al.  Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis , 2002, Nature Medicine.

[36]  R. Visse,et al.  Matrix Metalloproteinases Regulation and Dysregulation in the Failing Heart , 2002 .

[37]  M. Hollenberg,et al.  Mechanisms of action of proteinase‐activated receptor agonists on human platelets , 2002, British journal of pharmacology.

[38]  Z. Galis,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[39]  J. Isner,et al.  Endothelial Progenitor Cell Vascular Endothelial Growth Factor Gene Transfer for Vascular Regeneration , 2002, Circulation.

[40]  S. Verma,et al.  Fundamentals of endothelial function for the clinical cardiologist. , 2002, Circulation.

[41]  T. Sawamura,et al.  Lectin‐like oxidized low density lipoprotein receptor‐1 (LOX‐1) serves as an endothelial receptor for advanced glycation end products (AGE) , 2002, FEBS letters.

[42]  L. Fuentes,et al.  Secretory Phospholipase A2 Elicits Proinflammatory Changes and Upregulates the Surface Expression of Fas Ligand in Monocytic Cells: Potential Relevance for Atherogenesis , 2002, Circulation research.

[43]  T. Voyno-Yasenetskaya,et al.  Thrombin-Induced NF- B Activation and ICAM-1 Transcription in Endothelial Cells , 2002 .

[44]  J. Mehta,et al.  Transforming Growth Factor-β1 Modulates Oxidatively Modified LDL–Induced Expression of Adhesion Molecules: Role of LOX-1 , 2001 .

[45]  J. Manson,et al.  A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. , 2001, Journal of the American College of Cardiology.

[46]  David B. Leake,et al.  Inhibition of lipoprotein‐associated phospholipase A2 diminishes the death‐inducing effects of oxidised LDL on human monocyte‐macrophages , 2001, FEBS letters.

[47]  J. Isner,et al.  HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. , 2001, The Journal of clinical investigation.

[48]  A M Zeiher,et al.  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. , 2001, The Journal of clinical investigation.

[49]  T. Cocks,et al.  Increased Expression of Protease-Activated Receptor-2 (PAR2) and PAR4 in Human Coronary Artery by Inflammatory Stimuli Unveils Endothelium-Dependent Relaxations to PAR2 and PAR4 Agonists , 2001, Circulation research.

[50]  E. Topol,et al.  Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. , 2001, Circulation research.

[51]  S. Fichtlscherer,et al.  Number and Migratory Activity of Circulating Endothelial Progenitor Cells Inversely Correlate With Risk Factors for Coronary Artery Disease , 2001, Circulation research.

[52]  T. Cocks,et al.  Protease‐Activated Receptor (PAR) 1 but Not PAR2 or PAR4 Mediates Endothelium‐Dependent Relaxation to Thrombin and Trypsin in Human Pulmonary Arteries , 2001, Journal of cardiovascular pharmacology.

[53]  J. Holtz,et al.  Induction of the oxLDL receptor LOX-1 by endothelin-1 in human endothelial cells. , 2001, Biochemical and biophysical research communications.

[54]  T. Kita,et al.  Oxidized LDL Modulates Bax/Bcl-2 Through the Lectinlike Ox-LDL Receptor-1 in Vascular Smooth Muscle Cells , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[55]  D. Morrison,et al.  Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[56]  J. Wallace,et al.  Protease-activated receptors in inflammation, neuronal signaling and pain. , 2001, Trends in pharmacological sciences.

[57]  H. Ishizaka,et al.  Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. , 2001, American heart journal.

[58]  H. Mabuchi,et al.  Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis , 2001, Clinical chemistry and laboratory medicine.

[59]  T. Kita,et al.  Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[60]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[61]  K. Kugiyama,et al.  Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. , 2000, The American journal of cardiology.

[62]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[63]  S. Shapiro,et al.  Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. , 2000, The Journal of biological chemistry.

[64]  M. Yen,et al.  Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. , 2000, Atherosclerosis.

[65]  J. Mehta,et al.  Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. , 2000, Circulation.

[66]  C. Packard,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease , 2000 .

[67]  D. Stengel,et al.  Mildly oxidized LDL induces expression of group IIa secretory phospholipase A(2) in human monocyte-derived macrophages. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[68]  T. Sawamura,et al.  Oxidized Low Density Lipoprotein (ox-LDL) Binding to ox-LDL Receptor-1 in Endothelial Cells Induces the Activation of NF-κB through an Increased Production of Intracellular Reactive Oxygen Species* , 2000, The Journal of Biological Chemistry.

[69]  S. Coughlin,et al.  PAR3 is a cofactor for PAR4 activation by thrombin , 2000, Nature.

[70]  S. Narumiya,et al.  Increased Expression of Lectinlike Oxidized Low Density Lipoprotein Receptor-1 in Initial Atherosclerotic Lesions of Watanabe Heritable Hyperlipidemic Rabbits , 2000 .

[71]  J. Mehta,et al.  Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[72]  T. Aoyama,et al.  LOX‐1 mediates lysophosphatidylcholine‐induced oxidized LDL uptake in smooth muscle cells , 2000, FEBS letters.

[73]  S. Rafii,et al.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.

[74]  T. Sawamura,et al.  A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[75]  A. Clowes,et al.  Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. , 1999, Circulation research.

[76]  T. Häkkinen,et al.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[77]  M. D'Andrea,et al.  Altered vascular injury responses in mice deficient in protease-activated receptor-1. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[78]  Hirofumiyasue,et al.  Circulating Levels of Secretory Type II Phospholipase A2 Predict Coronary Events in Patients with Coronary Artery Disease , 1999 .

[79]  K. Kugiyama,et al.  Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. , 1999, Circulation.

[80]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[81]  J. Mehta,et al.  Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. , 1999, Circulation research.

[82]  W. Jaross,et al.  Analysis of secretory group II phospholipase A2 expression in human aortic tissue in dependence on the degree of atherosclerosis. , 1999, Atherosclerosis.

[83]  J. Qiao,et al.  Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[84]  J. Qiao,et al.  Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[85]  K. Schrör,et al.  Evidence for proteinase‐activated receptor‐2 (PAR‐2)‐mediated mitogenesis in coronary artery smooth muscle cells , 1999, British journal of pharmacology.

[86]  D. Tew,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.

[87]  H Shimokawa,et al.  Primary endothelial dysfunction: atherosclerosis. , 1999, Journal of molecular and cellular cardiology.

[88]  D. Steinberg,et al.  Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. , 1998, The Biochemical journal.

[89]  T. Kita,et al.  Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. , 1998, Circulation research.

[90]  J. Mehta,et al.  Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. , 1998, Biochemical and biophysical research communications.

[91]  P. Carmeliet,et al.  Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[92]  L. Elinder,et al.  Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[93]  R. Chambers,et al.  Thrombin Stimulates Smooth Muscle Cell Procollagen Synthesis and mRNA Levels via a PAR-1 Mediated Mechanism , 1998, Thrombosis and Haemostasis.

[94]  G. Amorino,et al.  Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. , 1998, The American journal of pathology.

[95]  T. Kita,et al.  An endothelial receptor for oxidized low-density lipoprotein , 1997, Nature.

[96]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[97]  P. Shah,et al.  Active oxygen species and lysophosphatidylcholine are involved in oxidized low density lipoprotein activation of smooth muscle cell DNA synthesis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[98]  M. Kasper,et al.  Secretory group II phospholipase A2 in human atherosclerotic plaques. , 1995, Atherosclerosis.

[99]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[100]  M. Cybulsky,et al.  Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. , 1992, The Journal of clinical investigation.

[101]  D. Steinberg,et al.  Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. , 1988, Proceedings of the National Academy of Sciences of the United States of America.